Skip to main content
Erschienen in:

25.01.2025 | AdisInsight Report

Flurpiridaz F 18: First Approval

verfasst von: Susan J. Keam

Erschienen in: American Journal of Cardiovascular Drugs | Ausgabe 1/2025

Einloggen, um Zugang zu erhalten

Abstract

Flurpiridaz F 18 (FLYRCADO™) is an intravenous (IV) radioactive diagnostic drug being developed by GE Healthcare and Lantheus Medical Imaging for use in positron emission tomography (PET) myocardial perfusion imaging (MPI) to detect coronary artery disease (CAD). In September 2024, flurpiridaz F 18 was approved in the USA for PET MPI under rest or stress (pharmacologic or exercise) in adult patients with known or suspected CAD to evaluate for myocardial ischemia and infarction. This article summarizes the milestones in the development of flurpiridaz F 18 leading to this first approval for use in PET MPI in adult patients to evaluate for myocardial ischemia and infarction.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Patel KK, Singh A, Bateman TM. The potential of F-18 flurpiridaz PET/CT myocardial perfusion imaging for precision imaging. Curr Cardiol Rep. 2022;24(8):987–94.CrossRefPubMed Patel KK, Singh A, Bateman TM. The potential of F-18 flurpiridaz PET/CT myocardial perfusion imaging for precision imaging. Curr Cardiol Rep. 2022;24(8):987–94.CrossRefPubMed
2.
Zurück zum Zitat GE Healthcare. GE HealthCare announces FDA approval of Flyrcado (flurpiridaz F 18) injection PET radiotracer for enhanced diagnosis of coronary artery disease [media release]. 27 Sep 2024. https://www.gehealthcare.com/. GE Healthcare. GE HealthCare announces FDA approval of Flyrcado (flurpiridaz F 18) injection PET radiotracer for enhanced diagnosis of coronary artery disease [media release]. 27 Sep 2024. https://​www.​gehealthcare.​com/​.
3.
Zurück zum Zitat Schindler TH, Bateman TM, Berman DS, et al. Appropriate Use Criteria for PET Myocardial Perfusion Imaging. J Nucl Med. 2020;61(8):1221–65.CrossRefPubMed Schindler TH, Bateman TM, Berman DS, et al. Appropriate Use Criteria for PET Myocardial Perfusion Imaging. J Nucl Med. 2020;61(8):1221–65.CrossRefPubMed
4.
Zurück zum Zitat Lantheus Medical Imaging, GE Healthcare. Lantheus and GE Healthcare announce the signing of a definitive license agreement for worldwide development and commercialization of flurpiridaz F 18 [media release]. 25 Apr 2017. https://www.lantheus.com/. Lantheus Medical Imaging, GE Healthcare. Lantheus and GE Healthcare announce the signing of a definitive license agreement for worldwide development and commercialization of flurpiridaz F 18 [media release]. 25 Apr 2017. https://​www.​lantheus.​com/​.
5.
Zurück zum Zitat Bourque JM. Cardiac PET perfusion imaging: AURORA lights the way to a new era. J Am Coll Cardiol. 2023;82(16):1611–3.CrossRefPubMed Bourque JM. Cardiac PET perfusion imaging: AURORA lights the way to a new era. J Am Coll Cardiol. 2023;82(16):1611–3.CrossRefPubMed
6.
Zurück zum Zitat Maddahi J, Czernin J, Lazewatsky J, et al. Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest. J Nucl Med. 2011;52(9):1490–8.CrossRefPubMed Maddahi J, Czernin J, Lazewatsky J, et al. Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest. J Nucl Med. 2011;52(9):1490–8.CrossRefPubMed
8.
Zurück zum Zitat Maddahi J. Properties of an ideal PET perfusion tracer: new PET tracer cases and data. J Nucl Cardiol. 2012;19(Suppl 1):S30–7.CrossRefPubMed Maddahi J. Properties of an ideal PET perfusion tracer: new PET tracer cases and data. J Nucl Cardiol. 2012;19(Suppl 1):S30–7.CrossRefPubMed
10.
Zurück zum Zitat Ahmed H, Haider A, Gisler L, et al. [18F]Flurpiridaz: facile and improved precursor synthesis for this next-generation cardiac positron emission tomography imaging agent. ChemMedChem. 2020;15(12):1040–3.CrossRefPubMed Ahmed H, Haider A, Gisler L, et al. [18F]Flurpiridaz: facile and improved precursor synthesis for this next-generation cardiac positron emission tomography imaging agent. ChemMedChem. 2020;15(12):1040–3.CrossRefPubMed
11.
Zurück zum Zitat US Food & Drug Administration. FDA approves imaging drug for evaluation of myocardial ischemia and infarction [media release]. 27 Sep 2024. https://www.fda.gov/. US Food & Drug Administration. FDA approves imaging drug for evaluation of myocardial ischemia and infarction [media release]. 27 Sep 2024. https://​www.​fda.​gov/​.
12.
Zurück zum Zitat Yu M, Guaraldi MT, Mistry M, et al. BMS-747158-02: a novel PET myocardial perfusion imaging agent. J Nucl Cardiol. 2007;14(6):789–98.CrossRefPubMed Yu M, Guaraldi MT, Mistry M, et al. BMS-747158-02: a novel PET myocardial perfusion imaging agent. J Nucl Cardiol. 2007;14(6):789–98.CrossRefPubMed
13.
Zurück zum Zitat Huisman MC, Higuchi T, Reder S, et al. Initial characterization of an 18F-labeled myocardial perfusion tracer. J Nucl Med. 2008;49(4):630–6.CrossRefPubMed Huisman MC, Higuchi T, Reder S, et al. Initial characterization of an 18F-labeled myocardial perfusion tracer. J Nucl Med. 2008;49(4):630–6.CrossRefPubMed
14.
Zurück zum Zitat Nekolla SG, Reder S, Saraste A, et al. Evaluation of the novel myocardial perfusion positron-emission tomography tracer 18F-BMS-747158-02: comparison to 13N-ammonia and validation with microspheres in a pig model. Circulation. 2009;119(17):2333–42.CrossRefPubMed Nekolla SG, Reder S, Saraste A, et al. Evaluation of the novel myocardial perfusion positron-emission tomography tracer 18F-BMS-747158-02: comparison to 13N-ammonia and validation with microspheres in a pig model. Circulation. 2009;119(17):2333–42.CrossRefPubMed
15.
Zurück zum Zitat Higuchi T, Nekolla SG, Huisman MM, et al. A new 18F-labeled myocardial PET tracer: myocardial uptake after permanent and transient coronary occlusion in rats. J Nucl Med. 2008;49(10):1715–22.CrossRefPubMed Higuchi T, Nekolla SG, Huisman MM, et al. A new 18F-labeled myocardial PET tracer: myocardial uptake after permanent and transient coronary occlusion in rats. J Nucl Med. 2008;49(10):1715–22.CrossRefPubMed
16.
Zurück zum Zitat Maddahi J, Bengel F, Huang SC, et al. Phase 1 rest-stress study of F-18 labeled BMS747158 myocardial perfusion PET tracer: human safety, dosimetry, biodistribution, and myocardial imaging characteristics [abstract no. 184]. J Nucl Med. 2009;50(Suppl 2). Maddahi J, Bengel F, Huang SC, et al. Phase 1 rest-stress study of F-18 labeled BMS747158 myocardial perfusion PET tracer: human safety, dosimetry, biodistribution, and myocardial imaging characteristics [abstract no. 184]. J Nucl Med. 2009;50(Suppl 2).
17.
Zurück zum Zitat Kawano M, Tsuchiya J, Bae H, et al. Phase I clinical study of NMB58, a novel positron emission tomography (PET)-myocardial perfusion imaging tracer, conducted to evaluate its safety and pharmacokinetics in Japanese healthy adult males. Ann Nucl Med. 2021;35(5):580–8.CrossRefPubMed Kawano M, Tsuchiya J, Bae H, et al. Phase I clinical study of NMB58, a novel positron emission tomography (PET)-myocardial perfusion imaging tracer, conducted to evaluate its safety and pharmacokinetics in Japanese healthy adult males. Ann Nucl Med. 2021;35(5):580–8.CrossRefPubMed
18.
Zurück zum Zitat Maddahi J, Agostini D, Bateman TM, et al. Flurpiridaz F-18 PET myocardial perfusion imaging in patients with suspected coronary artery disease. J Am Coll Cardiol. 2023;82(16):1598–610.CrossRefPubMed Maddahi J, Agostini D, Bateman TM, et al. Flurpiridaz F-18 PET myocardial perfusion imaging in patients with suspected coronary artery disease. J Am Coll Cardiol. 2023;82(16):1598–610.CrossRefPubMed
19.
Zurück zum Zitat Maddahi J, Lazewatsky J, Udelson JE, et al. Phase-III clinical trial of Fluorine-18 flurpiridaz positron emission tomography for evaluation of coronary artery disease. J Am Coll Cardiol. 2020;76(4):391–401.CrossRefPubMed Maddahi J, Lazewatsky J, Udelson JE, et al. Phase-III clinical trial of Fluorine-18 flurpiridaz positron emission tomography for evaluation of coronary artery disease. J Am Coll Cardiol. 2020;76(4):391–401.CrossRefPubMed
20.
Zurück zum Zitat Berman DS, Maddahi J, Tamarappoo BK, et al. Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography. J Am Coll Cardiol. 2013;61(4):469–77.CrossRefPubMed Berman DS, Maddahi J, Tamarappoo BK, et al. Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography. J Am Coll Cardiol. 2013;61(4):469–77.CrossRefPubMed
Metadaten
Titel
Flurpiridaz F 18: First Approval
verfasst von
Susan J. Keam
Publikationsdatum
25.01.2025
Verlag
Springer International Publishing
Erschienen in
American Journal of Cardiovascular Drugs / Ausgabe 1/2025
Print ISSN: 1175-3277
Elektronische ISSN: 1179-187X
DOI
https://doi.org/10.1007/s40256-024-00718-5

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Kardiologie

Dank Nasenspray seltener in die Notaufnahme

Durch die intranasale Applikation von Etripamil lassen sich paroxysmale supraventrikuläre Tachykardien (PSVT) oft in Eigenregie beenden. Das erspart den Betroffenen das Aufsuchen von Notfallambulanzen.

Vorhofflimmern: So häufig kommt es bei Katheterablation zu Embolien

Arterielle Embolien – insbesondere Hirnembolien - sind eine mögliche periprozedurale Komplikation bei Katheterablation von Vorhofflimmern. Wie hoch ist das Risiko? Eine Analyse von weltweit mehr als 300.000 Ablationsprozeduren gibt darüber Auskunft.

Extrakorporale Reanimation: Wechsel des EKG-Musters verschlechtert Prognose

Patientinnen und Patienten im Herzstillstand mit schockbarem Rhythmus, deren EKG-Muster sich später ändert, haben schlechtere Chancen. Eine Studiengruppe hat die Bedeutung eines solchen Rhythmuswechsels mit Blick auf die extrakorporale Reanimation genauer untersucht.

Leben retten dank Erste-Hilfe-App

Bei einem Herzstillstand zählt jede Minute bis eine Reanimation begonnen wird. Notfallmediziner Prof. Dr. med. Michael Müller erklärt im Interview, wie medizinisch geschulte Ersthelfende mittels App alarmiert werden können – und warum digitale Lösungen die Notfallversorgung revolutionieren könnten.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.